Skip to main content

Fenoldopam Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Sep 6, 2023.

Fenoldopam is also known as: Corlopam

Fenoldopam Pregnancy Warnings

Animal studies have revealed evidence of maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

The manufacturer makes no recommendation regarding use during pregnancy.

US FDA pregnancy category: Not assigned.

Risk Summary: Insufficient data exist to determine drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

See references

Fenoldopam Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

-According to some authorities, this drug is unlikely to adversely affect a nursing infant due to its poor oral bioavailability and short half-life.
-This drug can be administered intravenously to pediatric patients less than 1 month (at least 2 kg or full term).

See references

References for pregnancy information

  1. Product Information. Corlopam (fenoldopam). Neurex. 2001.

References for breastfeeding information

  1. Product Information. Corlopam (fenoldopam). Neurex. 2001.
  2. United States National Library of Medicine. Toxnet. Toxicology Data Network. 2013.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.